Pliant Therapeutics (PLRX) Stock Forecast, Price Target & Predictions
PLRX Stock Forecast
Pliant Therapeutics stock forecast is as follows: an average price target of $39.71 (represents a 230.92% upside from PLRX’s last price of $12.00) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
PLRX Price Target
The average price target for Pliant Therapeutics (PLRX) is $39.71 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $48.00 to $32.00. This represents a potential 230.92% upside from PLRX's last price of $12.00.
PLRX Analyst Ratings
According to 5 Wall Street analysts, Pliant Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for PLRX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Pliant Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 13, 2024 | Ed Arce | H.C. Wainwright | $38.00 | $11.84 | 220.95% | 216.67% |
| Sep 09, 2024 | Faisal Khurshid | Leerink Partners | $33.00 | $12.87 | 156.41% | 175.00% |
| May 23, 2024 | Yasmeen Rahimi | Piper Sandler | $40.00 | $13.85 | 188.81% | 233.33% |
| May 07, 2024 | Alex Thompson | Stifel Nicolaus | $32.00 | $13.91 | 130.05% | 166.67% |
| May 07, 2024 | Jeff Jones | Oppenheimer | $48.00 | $13.79 | 248.08% | 300.00% |
| May 07, 2024 | Ed Arce | H.C. Wainwright | $36.00 | $13.79 | 161.06% | 200.00% |
| May 07, 2024 | Brian Abrahams | RBC Capital | $45.00 | $13.79 | 226.32% | 275.00% |
| Dec 07, 2022 | - | J.P. Morgan | $42.00 | $17.18 | 144.47% | 250.00% |
The latest Pliant Therapeutics stock forecast, released on Sep 13, 2024 by Ed Arce from H.C. Wainwright, set a price target of $38.00, which represents a 220.95% increase from the stock price at the time of the forecast ($11.84), and a 216.67% increase from PLRX last price ($12.00).
Pliant Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 2 | 7 |
| Avg Price Target | $35.50 | $35.50 | $38.86 |
| Last Closing Price | $12.00 | $12.00 | $12.00 |
| Upside/Downside | 195.83% | 195.83% | 223.83% |
In the current month, the average price target of Pliant Therapeutics stock is $35.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 195.83% increase as opposed to Pliant Therapeutics's last price of $12.00. This month's average price target is down 0.00% compared to last quarter, and down -8.65% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 09, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 06, 2024 | Citigroup | Buy | Buy | Hold |
| May 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 07, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 07, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 07, 2024 | RBC Capital | Outperform | Outperform | Hold |
| May 07, 2024 | Citigroup | Buy | Buy | Hold |
| Mar 01, 2022 | RBC Capital | Outperform | Outperform | Hold |
Pliant Therapeutics's last stock rating was published by H.C. Wainwright on Sep 13, 2024. The company gave PLRX a "Buy" rating, the same as its previous rate.
Pliant Therapeutics Financial Forecast
Pliant Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $4.84M | - | $248.00K | $1.33M | $1.97M | $1.48M | - | $1.25M | $2.00M | $1.61M | $1.79M | $2.17M | $4.46M | $4.81M | $3.60M |
| Avg Forecast | $250.00K | $250.00K | $250.00K | $250.00K | $1.47M | $472.22K | $732.50K | $580.63K | $814.11K | $1.02M | $1.21M | $1.39M | $1.45M | $1.79M | $1.35M | $1.26M | $3.00M | $3.17M | $4.17M | $4.23M | $3.37M | $2.50M | $3.70M |
| High Forecast | $250.00K | $250.00K | $250.00K | $250.00K | $1.47M | $472.22K | $732.50K | $580.63K | $814.11K | $1.02M | $1.21M | $1.39M | $1.45M | $1.79M | $1.35M | $1.26M | $3.00M | $3.17M | $4.17M | $4.23M | $3.37M | $2.50M | $3.70M |
| Low Forecast | $250.00K | $250.00K | $250.00K | $250.00K | $1.47M | $472.22K | $732.50K | $580.63K | $814.11K | $1.02M | $1.21M | $1.39M | $1.45M | $1.79M | $1.35M | $1.26M | $3.00M | $3.17M | $4.17M | $4.23M | $3.37M | $2.50M | $3.70M |
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | 5.95% | - | 0.20% | 0.96% | 1.35% | 0.83% | - | 0.99% | 0.67% | 0.51% | 0.43% | 0.51% | 1.33% | 1.93% | 0.97% |
Pliant Therapeutics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $580.63K, with a low forecast of $580.63K, and a high forecast of $580.63K. PLRX's average Quarter revenue forecast represents a -88.00% decrease compared to the company's last Quarter revenue of $4.84M (Dec 23).
Pliant Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | $-46.57M | $-47.69M | $-47.33M | $-36.78M | $-34.74M | $-31.49M | - | $-27.76M | $-23.84M | $-26.66M | $-22.46M | $-22.50M | $-18.68M | $-16.20M | $-16.68M |
| Avg Forecast | $-199.90K | $-199.90K | $-199.90K | $-199.90K | $-1.18M | $-377.58K | $-585.70K | $-42.30M | $-650.96K | $-818.32K | $-969.50K | $-33.44M | $-1.16M | $-23.52M | $-1.08M | $-26.43M | $-26.35M | $-25.16M | $-22.46M | $-21.00M | $-2.69M | $-2.00M | $-10.30M |
| High Forecast | $-199.90K | $-199.90K | $-199.90K | $-199.90K | $-1.18M | $-377.58K | $-585.70K | $-33.84M | $-650.96K | $-818.32K | $-969.50K | $-26.75M | $-1.16M | $-18.82M | $-1.08M | $-21.15M | $-21.08M | $-20.12M | $-17.97M | $-16.80M | $-2.69M | $-2.00M | $-8.24M |
| Low Forecast | $-199.90K | $-199.90K | $-199.90K | $-199.90K | $-1.18M | $-377.58K | $-585.70K | $-50.76M | $-650.96K | $-818.32K | $-969.50K | $-40.12M | $-1.16M | $-28.22M | $-1.08M | $-31.72M | $-31.62M | $-30.19M | $-26.95M | $-25.20M | $-2.69M | $-2.00M | $-12.36M |
| Surprise % | - | - | - | - | - | - | - | - | 71.55% | 58.27% | 48.82% | 1.10% | 29.95% | 1.34% | - | 1.05% | 0.90% | 1.06% | 1.00% | 1.07% | 6.94% | 8.11% | 1.62% |
undefined analysts predict PLRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Pliant Therapeutics's previous annual EBITDA (undefined) of $NaN.
Pliant Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | $-41.11M | $-41.49M | $-41.19M | $-28.14M | $-34.60M | $-27.95M | - | $-27.88M | $-24.80M | $-27.05M | $-22.83M | $-22.86M | $-19.03M | $-16.53M | $-17.00M |
| Avg Forecast | $-61.39M | $-60.28M | $-59.88M | $-58.87M | $-59.63M | $-58.52M | $-51.24M | $-43.17M | $-49.12M | $-46.81M | $-43.07M | $-34.12M | $-42.27M | $-23.86M | $-48.89M | $-26.98M | $-27.11M | $-25.52M | $-22.83M | $-21.33M | $-42.68M | $-50.83M | $-10.49M |
| High Forecast | $-61.39M | $-60.28M | $-59.88M | $-58.87M | $-59.63M | $-53.20M | $-51.24M | $-34.53M | $-45.19M | $-46.81M | $-43.07M | $-27.30M | $-42.27M | $-19.09M | $-48.89M | $-21.58M | $-21.69M | $-20.42M | $-18.26M | $-17.07M | $-42.68M | $-50.83M | $-8.40M |
| Low Forecast | $-61.39M | $-60.28M | $-59.88M | $-58.87M | $-59.63M | $-67.98M | $-51.24M | $-51.80M | $-60.91M | $-46.81M | $-43.07M | $-40.95M | $-42.27M | $-28.63M | $-48.89M | $-32.37M | $-32.54M | $-30.63M | $-27.40M | $-25.60M | $-42.68M | $-50.83M | $-12.59M |
| Surprise % | - | - | - | - | - | - | - | - | 0.84% | 0.89% | 0.96% | 0.82% | 0.82% | 1.17% | - | 1.03% | 0.91% | 1.06% | 1.00% | 1.07% | 0.45% | 0.33% | 1.62% |
Pliant Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PLRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Pliant Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | $13.85M | $15.35M | $14.57M | $14.15M | $14.25M | $8.82M | - | $8.58M | $-47.27M | $7.67M | $5.47M | $6.57M | $5.63M | $4.59M | $3.04M |
| Avg Forecast | $2.25M | $2.25M | $2.25M | $2.25M | $13.26M | $4.25M | $6.60M | $5.23M | $7.33M | $9.22M | $10.92M | $12.50M | $13.07M | $16.14M | $12.16M | $11.35M | $-52.25M | $28.52M | $37.53M | $38.13M | $30.32M | $22.52M | $1.88M |
| High Forecast | $2.25M | $2.25M | $2.25M | $2.25M | $13.26M | $4.25M | $6.60M | $5.23M | $7.33M | $9.22M | $10.92M | $12.50M | $13.07M | $16.14M | $12.16M | $11.35M | $-41.80M | $28.52M | $37.53M | $38.13M | $30.32M | $22.52M | $2.25M |
| Low Forecast | $2.25M | $2.25M | $2.25M | $2.25M | $13.26M | $4.25M | $6.60M | $5.23M | $7.33M | $9.22M | $10.92M | $12.50M | $13.07M | $16.14M | $12.16M | $11.35M | $-62.69M | $28.52M | $37.53M | $38.13M | $30.32M | $22.52M | $1.50M |
| Surprise % | - | - | - | - | - | - | - | - | 1.89% | 1.66% | 1.33% | 1.13% | 1.09% | 0.55% | - | 0.76% | 0.90% | 0.27% | 0.15% | 0.17% | 0.19% | 0.20% | 1.62% |
Pliant Therapeutics's average Quarter SG&A projection for Mar 24 is $5.23M, based on 3 Wall Street analysts, with a range of $5.23M to $5.23M. The forecast indicates a -62.25% fall compared to PLRX last annual SG&A of $13.85M (Dec 23).
Pliant Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | $-0.69 | $-0.70 | $-0.00 | $-0.50 | $-0.71 | $-0.60 | - | $-0.77 | $-0.69 | $-0.75 | $-0.64 | $-0.64 | $-0.54 | $-0.47 | $-1.39 |
| Avg Forecast | $-1.02 | $-1.00 | $-0.99 | $-0.97 | $-0.99 | $-0.97 | $-0.85 | $-0.77 | $-0.81 | $-0.78 | $-0.71 | $-0.67 | $-0.70 | $-0.74 | $-0.81 | $-0.75 | $-0.76 | $-0.69 | $-0.67 | $-0.60 | $-0.71 | $-0.85 | $-0.86 |
| High Forecast | $-1.02 | $-1.00 | $-0.99 | $-0.97 | $-0.99 | $-0.88 | $-0.85 | $-0.77 | $-0.75 | $-0.78 | $-0.71 | $-0.67 | $-0.70 | $-0.74 | $-0.81 | $-0.75 | $-0.76 | $-0.69 | $-0.67 | $-0.60 | $-0.71 | $-0.85 | $-0.86 |
| Low Forecast | $-1.02 | $-1.00 | $-0.99 | $-0.97 | $-0.99 | $-1.13 | $-0.85 | $-0.77 | $-1.01 | $-0.78 | $-0.71 | $-0.67 | $-0.70 | $-0.74 | $-0.81 | $-0.75 | $-0.76 | $-0.69 | $-0.67 | $-0.60 | $-0.71 | $-0.85 | $-0.86 |
| Surprise % | - | - | - | - | - | - | - | - | 0.85% | 0.90% | 0.00% | 0.75% | 1.01% | 0.81% | - | 1.03% | 0.91% | 1.09% | 0.95% | 1.06% | 0.76% | 0.55% | 1.62% |
According to undefined Wall Street analysts, Pliant Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PLRX previous annual EPS of $NaN (undefined).
Pliant Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| ARVN | Arvinas | $25.05 | $75.36 | 200.84% | Buy |
| ETNB | 89bio | $8.48 | $22.00 | 159.43% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.12 | $36.00 | 88.28% | Buy |
| VRDN | Viridian Therapeutics | $22.06 | $37.83 | 71.49% | Buy |
| CYTK | Cytokinetics | $55.88 | $80.92 | 44.81% | Buy |
| MDGL | Madrigal Pharmaceuticals | $241.80 | $315.75 | 30.58% | Buy |
| DYN | Dyne Therapeutics | $34.06 | $43.88 | 28.83% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| ACLX | Arcellx | $76.89 | $61.00 | -20.67% | Buy |
PLRX Forecast FAQ
Is Pliant Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, Pliant Therapeutics (PLRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of PLRX's total ratings.
What is PLRX's price target?
Pliant Therapeutics (PLRX) average price target is $39.71 with a range of $32 to $48, implying a 230.92% from its last price of $12. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Pliant Therapeutics stock go up soon?
According to Wall Street analysts' prediction for PLRX stock, the company can go up by 230.92% (from the last price of $12 to the average price target of $39.71), up by 300.00% based on the highest stock price target, and up by 166.67% based on the lowest stock price target.
Can Pliant Therapeutics stock reach $20?
PLRX's average twelve months analyst stock price target of $39.71 supports the claim that Pliant Therapeutics can reach $20 in the near future.
What is Pliant Therapeutics's current price target trend?
2 Wall Street analysts forecast a $35.5 price target for Pliant Therapeutics (PLRX) this month, up 195.83% from its last price of $12. Compared to the last 3 and 12 months, the average price target increased by 195.83% and increased by 223.83%, respectively.
What are Pliant Therapeutics's analysts' financial forecasts?
Pliant Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $3.26M (high $3.26M, low $3.26M), average EBITDA is $-44.439M (high $-35.979M, low $-52.898M), average net income is $-213M (high $-199M, low $-231M), average SG&A $29.34M (high $29.34M, low $29.34M), and average EPS is $-3.577 (high $-3.489, low $-3.734). PLRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1M (high $1M, low $1M), average EBITDA is $-800K (high $-800K, low $-800K), average net income is $-240M (high $-240M, low $-240M), average SG&A $9.01M (high $9.01M, low $9.01M), and average EPS is $-3.982 (high $-3.982, low $-3.982).
Did the PLRX's actual financial results beat the analysts' financial forecasts?
Based on Pliant Therapeutics's last annual report (Dec 2023), the company's revenue was $1.58M, which missed the average analysts forecast of $4.44M by -64.40%. Apple's EBITDA was $-182M, beating the average prediction of $-35.876M by 408.15%. The company's net income was $-161M, missing the average estimation of $-173M by -6.81%. Apple's SG&A was $57.93M, beating the average forecast of $39.97M by 44.93%. Lastly, the company's EPS was $-2.75, missing the average prediction of $-2.97 by -7.42%. In terms of the last quarterly report (Dec 2023), Pliant Therapeutics's revenue was $4.84M, beating the average analysts' forecast of $814.11K by 494.51%. The company's EBITDA was $-46.573M, beating the average prediction of $-651K by 7054.53%. Pliant Therapeutics's net income was $-41.109M, missing the average estimation of $-49.123M by -16.31%. The company's SG&A was $13.85M, beating the average forecast of $7.33M by 88.95%. Lastly, the company's EPS was $-0.69, missing the average prediction of $-0.814 by -15.18%